18 results
8-K
EX-10.2
ATXI
Avenue Therapeutics Inc
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation
8-K
EX-10.1
ATXI
Avenue Therapeutics Inc
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
, without limitation: (i) all expenses incident to the issuance, delivery and qualification of the Securities (including all printing and engraving costs … or the securities laws of any other country; (vii) if applicable, the filing fees incident to the review and approval by the FINRA of the Placement Agents
424B3
2di1wrlroiq
4 May 23
Prospectus supplement
4:30pm
8-K
EX-1.1
m6xn6n4m9m 97qrfzodr
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
8-K
EX-1.1
21xnpvvh qb
13 Dec 21
Entry into a Material Definitive Agreement
9:23am
8-K
EX-1.1
t82ks6zh uam8vw4lys
10 Nov 21
Entry into a Material Definitive Agreement
5:22pm
8-K
EX-10.11
jg0 k5xscpg6d
11 Feb 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-3.1
j256uhpd0hdx
11 Feb 19
Entry into a Material Definitive Agreement
8:39am
DEFM14A
mg12xkyrngkai0h
21 Dec 18
Proxy related to merger
12:23pm
PREM14A
1ak9 elnr3
11 Dec 18
Preliminary proxy related to merger
5:23pm
8-K
EX-10.1
4olf0264
14 Nov 18
Entry into a Material Definitive Agreement
12:53pm
10-12G
EX-3.2
4w0k3mzon qbokfylcv
12 Jan 17
Registration of securities
12:00am
10-12G
EX-3.3
tsdezabxghoi
30 Dec 15
Registration of securities
12:00am
- Prev
- 1
- Next